Evidence map›Paper›PMID 32411125›Full record

ArticleFrontiers in immunology2020

Expansion of Neutrophils and Classical and Nonclassical Monocytes as a Hallmark in Relapsing-Remitting Multiple Sclerosis.

David Haschka, Piotr Tymoszuk, Gabriel Bsteh, Verena Petzer, Klaus Berek, Igor Theurl, Thomas Berger, Günter Weiss

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Immature CD10Frontiers in immunology · 2026
    Article
  6. Peripheral HLA-DRNeurology(R) neuroimmunology & neuroinflammation · 2025
    Article
  7. Review
  8. Article
  9. Current neuropharmacology · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. HLA-DRB1*15:01 and theNeurology(R) neuroimmunology & neuroinflammation · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

David HaschkaDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Piotr TymoszukDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Gabriel BstehDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Verena PetzerDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Klaus BerekDepartment of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
Igor TheurlDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Thomas BergerDepartment of Neurology, Medical University of Vienna, Vienna, Austria.
Günter WeissDepartment of Internal Medicine II, Medical University of Innsbruck, Innsbruck, Austria.
Innsbruck Medical University · ATUniversität Innsbruck · ATMedical University of Vienna · AT

Funding

Austrian Science Fund FWF I 3321Austrian Science Fund FWF P 28302Austrian Science Fund FWF W 1253
6 · The paper itself

Abstract

Neutrophils and monocytes encompassing the classical, intermediate, and nonclassical population constitute the majority of circulating myeloid cells in humans and represent the first line of innate immune defense. As such, changes in their relative and absolute amounts serve as sensitive markers of diverse inflammatory conditions. Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system, causing demyelination and axonal loss, affecting various neuron functions and often causing irreversible neurological disability. MS disease course is individually highly heterogeneous but can be classified as progressive (PMS) or relapsing-remitting (RRMS). Each MS course type may be further characterized as active or inactive, depending on the recent disability progression and/or current relapses. Data on specific alterations of the myeloid compartment in association with MS disease course are scarce and conflicting. In the current study, we systematically immunophenotyped blood myeloid leukocytes by flow cytometry in 15 healthy and 65 MS subjects. We found a highly significant expansion of granulocytes, CD15

Indexed as

AdultAgedBiomarkersFemaleFlow CytometryHumansImmunologic FactorsImmunophenotypingMaleMiddle AgedMonocytesMultiple Sclerosis, Relapsing-RemittingNatalizumabNeutrophilsBiomarkersImmunologic FactorsNatalizumabclassical monocytesmultiple sclerosisneutrophilsnonclassical monocytesrelapsing-remitting multiple sclerosis

Identifiers

PMID32411125
PMCPMC7202453
OpenAlexW3022089954

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.